Matches in Nanopublications for { ?s ?p "for all patients eplerenone tablets are contraindicated in all patients with serum potassium 5 5 meq l at initiation creatinine clearance 3 ml min or concomitant administration of strong cyp3a4 inhibitors e g ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir and nelfinavir see drug interactions 7 1 cyp3a4 inhibitors clinical pharmacology 12 3 pharmacokinetics for patients treated for hypertension eplerenone tablets is contraindicated for the treatment of hypertension in patients with type 2 diabetes with microalbuminuria serum creatinine 2 mg dl in males or 1 8 mg dl in females creatinine clearance 5 ml min or concomitant administration of potassium supplements or potassium sparing diuretics e g amiloride spironolactone or triamterene see warnings and precautions 5 1 hyperkalemia adverse reactions 6 2 clinical laboratory test findings 7 drug interactions clinical pharmacology 12 3 pharmacokinetics for all patients serum potassium 5 5 meq l at initiation 4 creatinine clearance 3 ml min 4 concomitant use with strong cyp3a4 inhibitors 4 7 1 for the treatment of hypertension type 2 diabetes with microalbuminuria 4 serum creatinine 2 mg dl in males 1 8 mg dl in females 4 creatinine clearance 5 ml min 4 concomitant use of potassium supplements or potassium sparing diuretics 4" ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- association label "for all patients eplerenone tablets are contraindicated in all patients with serum potassium 5 5 meq l at initiation creatinine clearance 3 ml min or concomitant administration of strong cyp3a4 inhibitors e g ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir and nelfinavir see drug interactions 7 1 cyp3a4 inhibitors clinical pharmacology 12 3 pharmacokinetics for patients treated for hypertension eplerenone tablets is contraindicated for the treatment of hypertension in patients with type 2 diabetes with microalbuminuria serum creatinine 2 mg dl in males or 1 8 mg dl in females creatinine clearance 5 ml min or concomitant administration of potassium supplements or potassium sparing diuretics e g amiloride spironolactone or triamterene see warnings and precautions 5 1 hyperkalemia adverse reactions 6 2 clinical laboratory test findings 7 drug interactions clinical pharmacology 12 3 pharmacokinetics for all patients serum potassium 5 5 meq l at initiation 4 creatinine clearance 3 ml min 4 concomitant use with strong cyp3a4 inhibitors 4 7 1 for the treatment of hypertension type 2 diabetes with microalbuminuria 4 serum creatinine 2 mg dl in males 1 8 mg dl in females 4 creatinine clearance 5 ml min 4 concomitant use of potassium supplements or potassium sparing diuretics 4" assertion.